Key Highlights

  • The sale of the Life Sciences and Healthcare unit finished October 6, 2026, delivering USD 488.4 million in net cash, below the USD 600 million headline price disclosed July 6.
  • The third-quarter net loss came to USD 80.8 million, or USD 0.13 per share, after a USD 62.2 million non-cash Goodwill write-down, compared with a USD 28.3 million loss a year earlier.
  • Adjusted Net Income advanced to USD 136.0 million, or USD 0.21 per diluted share, from USD 119.3 million and USD 0.18 on the company's adjusted measure.
  • Total Debt stood at USD 4,176.1 million at September 30, 2026, before sale proceeds; published market data showed a USD 2.33 price, up 11.24%, on 2.745 million shares.

Divestiture Closes Ahead of a Wider Quarterly Loss

Clarivate (NYSE:CLVT) released third-quarter 2026 figures on November 3, 2026, the first report to present its Life Sciences and Healthcare unit as discontinued. The buyer, an Investment firm named Altaris, agreed on July 6 to pay USD 600 million: USD 500 million at closing, USD 25 million deferred until a transition agreement expires and a USD 75 million seller note. The transaction closed October 6 with net cash of USD 488.4 million, and management said proceeds would go toward debt reduction. Revenue from continuing operations was USD 481.6 million against USD 530.3 million a year earlier, and the reported loss included the USD 62.2 million impairment.

Debt Arithmetic Before and After the Sale

Total debt was USD 4,176.1 million at September 30, 2026, a figure that predates the October proceeds. If the full USD 488.4 million went to lenders, the balance would fall to roughly USD 3.69 billion, a hypothetical built from two published numbers. Set against the midpoint of the continuing-operations adjusted EBITDA outlook, USD 865 million to USD 885 million, that would be about 4.2 times, also simple arithmetic. Free Cash Flow reached USD 110.2 million in the quarter, and the updated full-year outlook calls for USD 320 million to USD 340 million, alongside adjusted diluted EPS of USD 0.73 to USD 0.77. The release offered no like-for-like prior guidance, so a raise or cut cannot be confirmed.

Penny Stock Status and the Impairment Backdrop

At USD 2.33, Clarivate (NYSE:CLVT) sits under the USD 5 Penny Stock threshold used here, and the 11.24% gain on 2.745 million shares comes from published market data with an unconfirmed snapshot date. In a penny stock, a small number of trades can move the price, spreads can be wide and quoted gains can reverse, so nothing here implies continuation. Nine-month goodwill impairment reached USD 283.9 million, showing how much value was written down in the divested unit. Share repurchases totaled USD 18.1 million over nine months. Market Capitalization was not verified, and the adjusted figures exclude items the GAAP loss includes.

Where Things Stand

Plans point to debt reduction, though the release does not itemize it. Clarivate (NYSE:CLVT) received USD 488.4 million of net cash on October 6, 2026, a few days after its quarter closed, and said it intends to reduce borrowings from total debt of USD 4,176.1 million at September 30. Remaining operations guide to USD 865 million to USD 885 million of adjusted EBITDA for 2026. The next evidence is the fourth-quarter report and any disclosed paydown of notes, and the share price can move sharply on thin volume.